BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2025
0mins
Source: Yahoo Finance
Clinical Trial Announcement: BioStem Technologies has completed patient enrollment for its clinical trial comparing BioREtain® Amnion Chorion (BR-AC) allograft to standard care for non-healing diabetic foot ulcers, with topline results expected in Q4 2025.
Market Context: Diabetic foot ulcers affect a significant portion of the diabetic population, leading to serious complications and substantial healthcare costs, estimated between $9 billion and $13 billion annually in the U.S.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
